Extended‐release methylphenidate for treatment of amphetamine/methamphetamine dependence: a randomized, double‐blind, placebo‐controlled trial

Miles, S. Wayne; Sheridan, Janie; Russell, Bruce; Kydd, Robert R.; Wheeler, Amanda; Walters, Carina; Gamble, Greg; Hardley, Peta; Jensen, Maree; Kuoppasalmi, Kimmo; Tuomola, Pekka; Föhr, Jaana; Kuikanmäki, Outi; Vorma, Helena; Salokangas, Raimo K. R.; Mikkonen, Antti; Kallio, Mika; Kauhanen, Jussi; Kiviniemi, Vesa; Tiihonen, Jari

doi:10.1111/add.12109

Cited by 60 publications

(71 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Methylphenidate treatment (20 weeks) was also tested in a randomized, placebo-controlled trial in Finnish amphetamine/methamphetaminedependent patients; results showed reduced percentage of amphetaminepositive urine samples, and methylphenidate was therefore suggested as a potential substitution therapy (Tiihonen et al, 2007). A later parallel-group, double-blind, randomized, placebo-controlled study in amphetamine/ methamphetamine-dependent outpatients administered methylphenidate for 22 weeks, but did not find a superior effect of methylphenidate over placebo in positive urine samples, drug use, or craving (Miles et al, 2013). Overall, psychostimulant medications only occasionally work as replacement therapies and may need patient collectives to be further differentiated for a more personalized treatment (Perez-Mana, Castells, Torrens, Capella, & Farre, 2013).…”

Section: Methylphenidatementioning

confidence: 99%

Psychostimulants

McCreary

Müller

Filip

2015

International Review of Neurobiology

View full text Add to dashboard Cite

Section: Methylphenidatementioning

confidence: 99%

Psychostimulants

McCreary

Müller

Filip

2015

International Review of Neurobiology

View full text Add to dashboard Cite

“…These medications include ondansetron (Johnson et al, 2008), methylphenidate (Miles et al, 2013), a combination of flumazenil, gabapentin and hydroxyzine (Ling et al, 2012), modafinil (Shearer et al, 2009), topiramate (Johnson et al., 2007), aripiprazole (Newton et al, 2008), sertraline (Zorick et al, 2011), and isradipine (Johnson et al, 2005). Unfortunately, none of these medications have shown associated reductions in subjective methamphetamine craving, and two of these medications, namely aripiprazole and sertraline, have even been associated with increased (Newton et al, 2008) or sustained (Zorick et al, 2011) craving following treatment, respectively.…”

Section: Treatment Of Methamphetamine Use Disordersmentioning

confidence: 99%

Methamphetamine: An update on epidemiology, pharmacology, clinical phenomenology, and treatment literature

Courtney

Ray

2014

Drug and Alcohol Dependence

374

255

View full text Add to dashboard Cite

Background-Despite initial reports of a decline in use in the early 2000s, methamphetamine remains a significant public health concern with known neurotoxic and neurocognitive effects to the user. The goal of this review is to update the literature on methamphetamine use and addiction since its assent to peak popularity in 1990s.Methods-Specifically, we first review recent epidemiological reports with a focus on methamphetamine accessibility, changes in use and disorder prevalence rates over time, and accurate estimates of the associated burden of care to the individual and society. Second, we review methamphetamine pharmacology literature with emphasis on the structural and functional neurotoxic effects associated with repeated use of the drug. Third, we briefly outline the findings on methamphetamine-related neurocognitive deficits as assessed via behavioral and neuroimaging paradigms. Lastly, we review the clinical presentation of methamphetamine addiction and the evidence supporting the available psychosocial and pharmacological treatments within the context of an addiction biology framework.Conclusion-Taken together, this review provides a broad-based update of the available literature covering methamphetamine research over the past two decades and concludes with recommendations for future research.

show abstract

“…However, results from the only randomized, double-blind, placebo-controlled trial of SR-methylphenidate were not positive, although retention was poor (35%) [124]. Clearly, additional studies are needed.…”

Section: Dopaminergic Pharmacotherapiesmentioning

confidence: 99%

Pharmacotherapeutics for substance-use disorders: a focus on dopaminergic medications

Verrico

Haile

Newton

et al. 2013

Expert Opinion on Investigational Drugs

View full text Add to dashboard Cite

Introduction Illicit substance-use is a substantial public health concern, contributing over $150 billion in costs annually to Americans. A complex disease, a substance-use disorder affects neural circuits involved in reinforcement, motivation, learning and memory, and inhibitory control. Areas covered The modulatory influence of dopamine in mesocorticolimbic circuits contributes to encoding the primary reinforcing effects of substances and numerous studies suggest that aberrant signaling within these circuits contributes to the development of a substance-use disorder in some individuals. Decades of research focused on the clinical development of medications that directly target dopamine receptors has led to recent studies of agonist-like dopaminergic treatments for stimulant-use disorders and, more recently, cannabis-use disorder. Human studies evaluating the efficacy of dopaminergic agonist-like medications to reduce reinforcing effects and substance-use provide some insight into the design of future pharmacotherapy trials. A search of PubMed using specific brain regions, medications, and/or the terms ‘dopamine’, ‘cognition’, ‘reinforcement’, ‘cocaine’, ‘methamphetamine’, ‘amphetamine’, ‘cannabis’, ‘treatment/pharmacotherapy’, ‘addiction/abuse/dependence’ identified articles relevant to this review. Expert opinion Conceptualization of substance-use disorders and their treatment continues to evolve. Current efforts increasingly focus on a strategy fostering combination pharmacotherapies that target multiple neurotransmitter systems.

show abstract

Extended‐release methylphenidate for treatment of amphetamine/methamphetamine dependence: a randomized, double‐blind, placebo‐controlled trial

Cited by 60 publications

References 31 publications

Psychostimulants

Psychostimulants

Methamphetamine: An update on epidemiology, pharmacology, clinical phenomenology, and treatment literature

Pharmacotherapeutics for substance-use disorders: a focus on dopaminergic medications

Contact Info

Product

Resources

About